Loading
Old version — revision 1
This is a fixed snapshot of Enhancement in sport, saved by Import as part of the initial corpus import. It is not edited and it is not updated; the article may have changed since.
Edit summary: Initial import of content/enhancement-in-sport.md — the filesystem corpus, unchanged. Not an edit.
The regulation of performance enhancement in competition, the only domain that draws an operational line between therapy and enhancement and litigates it case by case.
Enhancement in sport is the use of substances, methods and equipment to raise athletic performance, and the regulatory apparatus built to prohibit some of it. Sport is unusual among human activities in maintaining a formal, enforced boundary between restoring health and exceeding it, complete with a list of banned agents, a testing infrastructure, an appeals court, and a procedure for granting exemptions. That machinery makes it the best available case study for what happens when the therapy–enhancement distinction described in Human enhancement is turned into administrative law.
Anti-doping predates the World Anti-Doping Agency by decades, but the modern system dates from the 1998 Tour de France, when a team car full of doping products was intercepted and the resulting scandal made clear that federations could not police themselves. WADA was established the following year as a joint initiative of the Olympic movement and governments, and the World Anti-Doping Code came into force in 2004. It has been revised several times since.
Its central features are an annually revised Prohibited List, accredited laboratories, out-of-competition testing with whereabouts requirements, and strict liability: an athlete is responsible for what is in their body regardless of intent, subject to reduced sanction where fault is minimal — the provision that governs the recurring disputes over contaminated supplements. Disputes go to the Court of Arbitration for Sport.
Detection has shifted from finding a molecule to characterising a person. The Athlete Biological Passport, introduced for blood variables in 2009 and extended to steroid profiles, tracks each athlete against their own longitudinal baseline and flags deviations whose cause need not be identified. This is the model anti-doping science expects to rely on as agents become harder to detect directly, and it is the approach discussed in Gene doping for interventions that leave no foreign molecule at all.
A substance or method is added to the Prohibited List if it meets two of three criteria: it enhances or could enhance performance; it poses an actual or potential health risk; and it violates the spirit of sport. Masking agents are included regardless. The list therefore mixes categories that have little in common pharmacologically: anabolic agents and the muscle-directed constructs discussed in Myostatin inhibition, hormones, diuretics, and the stimulants and wakefulness drugs covered in Nootropics.
Each criterion carries a different justification and each is contested.
Health. The paternalism objection is answered by the coercion argument: in a competitive setting, one athlete's use imposes a choice on everyone else, so protecting health is protecting against a collective-action failure rather than against individual foolishness. The historical case that grounds this is East Germany's state doping programme, which administered androgens to athletes including minors and produced documented long-term harm. The structure is the one set out in Enhancement arms race.
Fairness. The difficulty is that sport does not equalise anything else. Athletes differ in genes, altitude of birthplace, national funding and access to coaching, and none of this is levelled. The fairness argument therefore has to explain why pharmacological advantage is different from every other kind, which it does mainly by pointing to concealment and to the absence of consent.
Spirit of sport. The Code lists values — health, excellence, character, respect for rules, courage, community — and the criterion has been criticised as the point at which the system stops giving reasons. It is nonetheless the criterion that decides the hard cases, since many prohibited substances would fail the first two tests on their own.
The list is not a principleCaffeine was prohibited until 2004 and is now merely monitored. Hypoxic tents, which raise red-cell mass by the same physiological route as a banned hormone, were examined by WADA's ethics panel in 2006 and judged contrary to the spirit of sport, and were then not prohibited. The list records a series of negotiated decisions rather than the application of a consistent rule.
The therapeutic-use exemption is where the therapy–enhancement line becomes an actual decision by an actual committee. An athlete may use a prohibited substance if withholding it would cause significant health impairment, if it produces no enhancement beyond a return to normal health, and if no permitted alternative exists.
The middle condition is the hard one. Restoring an asthmatic athlete's lung function to normal is by construction a performance improvement relative to their untreated state, and there is no non-arbitrary way to identify the baseline the exemption is supposed to return them to. The 2016 publication of stolen exemption records, showing widespread and lawful use of powerful medications by prominent athletes, made the tension public without producing a resolution. The system's defence is that the alternative — refusing treatment to sick athletes — is worse, which is true and is not an answer to the conceptual objection.
Governing bodies regulate equipment on a logic that parallels doping and produces the same inconsistencies. Polyurethane swimsuits that reduced drag and improved buoyancy were permitted through a period of extraordinary record-setting in 2008 and 2009, then banned. Distance-running shoes with thick compliant midsoles and embedded plates measurably improved running economy and were restricted by a stack-height rule rather than prohibited. Neither decision was framed as protecting health. Powered assistance of the kind described in Powered exoskeletons has never needed a rule, because no federation has had to consider admitting it.
Prosthetic athletes force the question directly. When Oscar Pistorius, a double transtibial amputee, sought to compete against non-amputees, athletics' governing body ruled him ineligible on the basis of a biomechanical study finding a mechanical advantage from his carbon-fibre blades; the Court of Arbitration for Sport overturned the ruling in 2008, holding that an overall advantage had not been proved, and he competed at the 2012 Olympics.1 The scientists involved subsequently disagreed in print about what the measurements showed, since the blades are lighter and return energy more efficiently than a biological limb while providing far less force at the start and less stability.2 The unresolved case is the long jumper Markus Rehm, whose distances are competitive at the highest level and who has not been able to satisfy the requirement to prove no advantage — a burden of proof that, applied symmetrically, no athlete could meet.
The prosthetics themselves are covered in Myoelectric prosthetics and Osseointegration; the relevant point here is that a device classed as a medical aid in one setting is classed as potential enhancement in another, with no change to the device. Paralympic classification faces the mirror-image problem of grouping impairments finely enough to make competition meaningful, and the disputes it generates are examined in Disability rights and enhancement.
Regulations on athletes with differences of sex development require testosterone suppression for eligibility in some women's events, on the argument that endogenous androgen levels in a typical male range confer a performance advantage that categories exist to control. Caster Semenya challenged the rules through arbitration and the Swiss courts without success, and then before the European Court of Human Rights, where a chamber found in her favour in 2023 and the Grand Chamber upheld part of her case in 2025, on the adequacy of the judicial review she had received in Switzerland rather than on the science. Neither judgment struck down the eligibility rules, which remain in force.3
The case is the sharpest illustration of the field's central difficulty. Every other criterion in anti-doping concerns something an athlete did. This one concerns something an athlete is, and requires a medical intervention to remove a natural characteristic in order to compete — the inverse of the therapy–enhancement relation everywhere else in the Code.
The Enhanced Games, announced in 2023 and backed by private investors, proposes competition with no anti-doping rules and medical supervision instead, on the argument that prohibition drives use underground and makes it more dangerous. An inaugural event was scheduled for Las Vegas in mid-2026; its conduct and outcome fall outside what this article can report. International federations have condemned the venture, and world governing bodies in at least one sport have moved to bar participants from their own competitions.
The argument deserves a serious answer rather than dismissal. Its weakest point is that supervision does not make unapproved agents safe, and that the people accepting the physiological risk are not the people capitalising the event. Its strongest point is that the existing regime spends heavily to enforce a line whose intellectual basis, as the exemption and equipment cases show, is not stable. The underlying dispute is the one set out in Bioethics of enhancement, with the unusual feature that one side has a testing budget and the other has a venue.
Anti-doping is criticised from three directions at once: as ineffective, since detection lags administration and the biological passport produces sanctions slowly and rarely; as unjust, since its burdens fall hardest on athletes from countries with the least legal support; and as incoherent, for the reasons set out above. Defenders reply that no regime with these aims could be fully coherent, and that the counterfactual is the 1990s, when entire pelotons were doped and athletes died. The claim to bodily self-determination advanced in Morphological freedom has never had much purchase here, because entry into competition is voluntary and the rules are a condition of it.
The technical pressure is toward interventions the current system cannot see: expression-modulating agents that add no foreign sequence, transient delivery that clears the body, and interventions targeting ageing biology whose performance effects are indirect. If detection cannot keep pace, the choice narrows to profiling every athlete continuously — which raises the privacy problems examined in Genetic discrimination and, for neural interventions, Mental privacy — or to accepting that some enhancement will go unpunished. Neither branch preserves the position the Code currently occupies.
lawCourt of Arbitration for Sport. Pistorius v. International Association of Athletics Federations, CAS 2008/A/1480.↩The award turned on the federation failing to prove an overall advantage, and decides only that athlete's eligibility.
paperWeyand, P. G. and Bundle, M. W. "Point: Artificial limbs do make artificially fast running speeds possible." Journal of Applied Physiology, 2009, with the accompanying counterpoint by Kram, Grabowski, McGowan, Brown and Herr.↩Published as a paired point and counterpoint by researchers who had worked on the same measurements and read them oppositely.
lawEuropean Court of Human Rights. Semenya v. Switzerland, Chamber judgment 2023 and Grand Chamber judgment 2025. ↩